Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
667
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Alopecia areata treatment with baricitinib: different relapse phenotypes

Federica Dall’OglioDermatology Clinic, University of Catania, Catania, ItalyView further author information
,
Maria Rita NascaDermatology Clinic, University of Catania, Catania, ItalyView further author information
,
Francesco LacarrubbaDermatology Clinic, University of Catania, Catania, ItalyView further author information
,
Pasquale VitaleDermatology Clinic, University of Catania, Catania, ItalyView further author information
&
Giuseppe MicaliDermatology Clinic, University of Catania, Catania, ItalyCorrespondence[email protected]
View further author information
Article: 2324832 | Received 22 Feb 2024, Accepted 23 Feb 2024, Published online: 11 Mar 2024

References

  • De la Torre-Gomar FJ, Velasco-Amador JP, Prados-Carmona Á, et al. Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib. J Dermatolog Treat. 2024;35(1):1. doi: 10.1080/09546634.2024.2304630.
  • Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–2. doi: 10.1007/s40257-023-00764-w.
  • Yan D, Fan H, Chen M, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450. doi: 10.3389/fphar.2022.950450.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.